Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 718

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

Tibes, Raoul, Qiu, YiHua, Lu, Yiling, Hennessy, Bryan, Andreeff, Michael, Mills, Gordon B., Kornblau, Steven M.·2006·Molecular Cancer Therapeutics

Abstract

Proteomics has the potential to provide answers in cancer pathogenesis and to direct targeted therapy through the comprehensive analysis of protein expression levels and activation status. The realization of this potential requires the development of new, rapid, high-throughput technologies for performing protein arrays on patient samples, as well as novel analytic techniques to interpret them. Herein, we describe the validation and robustness of using reverse phase protein arrays (RPPA) for the analysis of primary acute myelogenous leukemia samples as well as leukemic and normal stem cells. In this report, we show that array printing, detection, amplification, and staining precision are very high, reproducible, and that they correlate with traditional Western blotting. Using replicates of the same sample on the same and/or separate arrays, or using separate protein samples prepared from the same starting sample, the intra- and interarray reproducibility was extremely high. No statistically significant difference in protein signal intensities could be detected within the array setups. The activation status (phosphorylation) was maintained in experiments testing delayed processing and preparation from multiple freeze-thawed samples. Differences in protein expression could reliably be detected in as few as three cell protein equivalents. RPPA prepared from rare populations of normal and leukemic stem cells were successfully done and showed differences from bulk populations of cells. Examples show how RPPAs are ideally suited for the large-scale analysis of target identification, validation, and drug discovery. In summary, RPPA is a highly reliable, reproducible, high-throughput system that allows for the rapid large-scale proteomic analysis of protein expression and phosphorylation state in primary acute myelogenous leukemia cells, cell lines, and in human stem cells. [Mol Cancer Ther 2006;5(10):2512–21]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-06-0334

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 7

  1. Diks SH, Peppelenbosch MP. Single cell proteomics for personalised medicine. Trends Mol Med 2004;10:574–7. · doi:10.1016/j.molmed.2004.10.005
  2. Cui JW, Wang J, He K, et al. Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 2004;10:6887–96. · doi:10.1158/1078-0432.ccr-04-0307
  3. Juan HF, Lin JY, Chang WH, et al. Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatic analytical methods. Electrophoresis 2002;23:2490–504. · doi:10.1002/1522-2683(200208)23:15<2490::aid-elps2490>3.0.co;2-3
  4. Wan J, Wang J, Cheng H, et al. Proteomic analysis of apoptosis initiation induced by all-trans retinoic acid in human acute promyelocytic leukemia cells. Electrophoresis 2001;22:3026–37. · doi:10.1002/1522-2683(200108)22:14<3026::aid-elps3026>3.0.co;2-8
  5. Ota J, Yamashita Y, Okawa K, et al. Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncogene 2003;22:5720–8. · doi:10.1038/sj.onc.1206855
  6. Tibes R, Qui YH, Coombes KR, Gold D, Mills GB, Kornblau SM. Classification of acute myelogenous leukemia (AML) based on patterns of signal transduction pathway (STP) and apoptosis regulating protein activation determined by reverse phase proteins arrays (RPPA). Blood 2005;106:145a. · doi:10.1182/blood.v106.11.484.484
  7. Tibes R, Liu Y, Siwak D, Hennessy B, LaPushin R, Mills GB. Identification of selective inhibition of phospho-S6 ribosomal protein in XK469 sensitive leukemia cell lines using functional proteomic analysis. Proc Am Assoc Cancer Res 2005;46:772.

Cited by

See all 718

Metadata

Authors
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M.
Venue
Molecular Cancer Therapeutics
Published
2006-10-01
Volume
5
Issue
10
Pages
2512-2521
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2126983941
Cited by
718
References
16
FWCI
7.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0334
The paper
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006). Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.